CellDrive 3D

celldrive3d.com ↗ ·Boecillo ·Pre-seed

CellDrive 3D is a Boecillo-based biotechnology company developing advanced bioinks for 3D bioprinting in tissue engineering and regenerative medicine. It was spun out of the BIOFORGE research group at the University of Valladolid. Its patented modular platform is built on genetically engineered protein polymers inspired by human elastin. The platform produces synthetic, animal-component-free bioinks that support cell adhesion and proliferation and stay stable after printing without crosslinkers or photoinitiators. The technology is patent-protected in Europe, the United States, China and Japan. Founded in December 2020, the company received early-stage investment from BeAble Capital through its BeAble INNVIERTE KETs Fund, with participation from SODICAL. In 2023 it was awarded a €325,000 CDTI Neotec grant.

Founded

2020

Founders

Total funds raised

€169K

SectorsBiotechnology, 3D Bioprinting, Biomaterials, Regenerative Medicine Start-up MapHealthtech & Bio › R&D tools & software for life sciences

Suggest a correction

Founders

José Carlos Rodríguez-Cabello

Co-founder & Chief Scientific Adviser

Global models 5

Aspect Biosystems

Canada · www.aspectbiosystems.com ↗

Builds its business on proprietary bioprinting and bioink technology for tissue engineering and regenerative medicine, moving from platform partnerships towards bioprinted tissue therapeutics.

$150MComparable

Geltor

United States · geltor.com ↗

Designs animal-free recombinant protein biomaterials (collagen, elastin) and licenses or sells them as ingredients, close to CellDrive 3D's engineered elastin-like protein polymer platform.

$114MComparable

Inventia Life Science

Australia · inventia.life ↗

Sells a bioprinting platform together with its own consumable synthetic bioinks to research and pharma labs for 3D tissue models.

$40MComparable

CollPlant Biotechnologies

Israel · collplant.com ↗

Produces patented plant-derived recombinant human collagen bioinks for 3D bioprinting and regenerative medicine, and licenses them to medtech partners, the same animal-free protein-bioink model.

$30MComparable

CELLINK

Sweden · www.cellink.com ↗

Grew from selling proprietary bioinks, later adding bioprinters, to tissue-engineering researchers, before listing publicly and raising most of its capital on the stock market.

$5MComparable